

# Peripheral Arterial Disease Pipeline, Clinical Trials, Emerging Drugs Approvals and Companies | DelveInsight

---

## *Peripheral Arterial Disease Pipeline*

LAS VEGAS, NV, UNITED STATES, January 22, 2025 /EINPresswire.com/ -- DelveInsight's, "Peripheral Arterial Disease Pipeline Insight" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Peripheral Arterial Disease pipeline landscape. It covers the pipeline drug profiles, including Peripheral Arterial Disease clinical trials and nonclinical stage products. It also covers the Peripheral Arterial Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Peripheral Arterial Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ [Peripheral Arterial Disease Pipeline Outlook](#)

### Key Takeaways from the Peripheral Arterial Disease Pipeline Report

- In January 2025:- Novo Nordisk A/S:- This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo ("dummy") medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some countries. Participants will get the study medicine (semaglutide or placebo) in a pre-filled pen for injection.
- DelveInsight's Peripheral Arterial Disease pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Peripheral Arterial Disease treatment.
- The leading Peripheral Arterial Disease Companies such as Novo Nordisk, Helixmith, AdvanceCor, Venturis Therapeutics, VivaCell Biotechnology, Humacyte, Bayer, Vasa Therapeutics, and others.
- Promising Peripheral Arterial Disease Therapies such as Inclisiran Sodium, CSL300, Rivaroxaban 2.5mg, Temeirolimus, Sarpogrelate Sustained Release/Aspirin, NL003, and others

Stay ahead with the most recent pipeline outlook for Peripheral Arterial Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ [Peripheral Arterial Disease Treatment Drugs](#)

Peripheral Arterial Disease Emerging Drugs Profile

- Semaglutide: Novo Nordisk

Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Peripheral Artery Disease.

- VM202: Helixmith

VM202 is an investigational gene therapy being developed by Helixmith, formerly known as ViroMed. Helixmith's non-viral plasmid DNA product, Engensis, is designed to express recombinant HGF protein in nerve and Schwann cells to promote nerve system regeneration and induce the formation of microvascular blood vessels. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Peripheral Artery Disease.

- Revacept: AdvanceCor

Revacept is the first Fc-fusion protein to be used as pharmaceutical in stroke and heart attack. With its GPVI component, Revacept binds to damaged blood vessel walls, covers them and thus forms a kind of vascular patch. This prevents the formation of thrombi in the arteries. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Peripheral Artery Disease.

Explore groundbreaking therapies and clinical trials in the Peripheral Arterial Disease Pipeline. Access DelveInsight's detailed report now! @ New [Peripheral Arterial Disease Drugs](#)

#### Peripheral Arterial Disease Companies

Novo Nordisk, Helixmith, AdvanceCor, Venturis Therapeutics, VivaCell Biotechnology, Humacyte, Bayer, Vasa Therapeutics, and others.

Peripheral Arterial Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

- Intravenous
- Subcutaneous
- Oral
- Intramuscular

Peripheral Arterial Disease Products have been categorized under various Molecule types such as

- Monoclonal antibody
- Small molecule
- Peptide

Unveil the future of Peripheral Arterial Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Peripheral Arterial Disease Market Drivers and Barriers- <https://www.delveinsight.com/sample-request/peripheral->

[arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=ypr](https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr)

## Scope of the Peripheral Arterial Disease Pipeline Report

- Coverage- Global
- Peripheral Arterial Disease Companies- Novo Nordisk, Helixmith, AdvanceCor, Venturis Therapeutics, VivaCell Biotechnology, Humacyte, Bayer, Vasa Therapeutics, and others.
- Peripheral Arterial Disease Therapies- Inclisiran Sodium, CSL300, Rivaroxaban 2.5mg, Temezirolimus, Sarpogrelate Sustained Release/Aspirin, NL003, and others
- Peripheral Arterial Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Peripheral Arterial Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Peripheral Arterial Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Peripheral Arterial Disease Companies, Key Products and Unmet Needs- [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=ypr](https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr)

## Table of Content

1. Introduction
2. Executive Summary
3. Peripheral Arterial Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peripheral Arterial Disease – DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Peripheral Arterial Disease Collaboration Deals
9. Late Stage Products (Phase III)
10. Semaglutide: Novo Nordisk
11. Drug profiles in the detailed report.....
12. Mid Stage Products (Phase II)
13. VM202: Helixmith
14. Drug profiles in the detailed report.....
15. Early stage products (Phase I)
16. Revacept: AdvanceCor
17. Drug profiles in the detailed report.....
18. Inactive Products
19. Peripheral Arterial Disease Key Companies
20. Peripheral Arterial Disease Key Products
21. Peripheral Arterial Disease Unmet Needs
22. Peripheral Arterial Disease Market Drivers and Barriers

23. Peripheral Arterial Disease Future Perspectives and Conclusion
24. Peripheral Arterial Disease Analyst Views
25. Peripheral Arterial Disease Key Companies
26. Appendix

#### List of Top Selling Market Research Reports in 2025

Varicose Vein Treatment Devices Market - <https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market>

Vascular Access Devices Market - <https://www.delveinsight.com/report-store/vascular-access-device-market>

Indwelling Catheters Market - <https://www.delveinsight.com/report-store/indwelling-catheters-market>

Healthcare Competitive Benchmarking - <https://www.delveinsight.com/consulting/competitive-benchmarking-services>

Lymphoedema Market - <https://www.delveinsight.com/report-store/lymphoedema-market>

Pacemakers Market - <https://www.delveinsight.com/report-store/pacemakers-market>

Myeloproliferative Neoplasms Market - <https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market>

Surgical Mask & Respirator Market - <https://www.delveinsight.com/report-store/surgical-mask-respirator-market>

Nk Cell Therapy Market - <https://www.delveinsight.com/report-store/nk-cell-therapy-market>

Novel Drug Delivery Devices Market - <https://www.delveinsight.com/report-store/novel-drug-delivery-devices>

Testicular Neoplasm Market - <https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight>

Phototherapies For Psoriasis Market - <https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market>

Skin Neoplasm Market - <https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market>

Microscopy Device Market - <https://www.delveinsight.com/report-store/microscopy-device-market>

Bone Growth Stimulator Market - <https://www.delveinsight.com/report-store/bone-growth-stimulators-market>

Urea Cycle Disorders Market - <https://www.delveinsight.com/report-store/urea-cycle-disorders-market>

Antibody Drug Conjugate Market - <https://www.delveinsight.com/report-store/antibody-drug-conjugate-market>

Total Knee Arthroplasty Market - <https://www.delveinsight.com/report-store/total-knee-arthroplasty-market>

Cardiac Implantable Electronic Devices Market - <https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market>

Dyspepsia Market - <https://www.delveinsight.com/report-store/functional-dyspepsia->

[epidemiology-forecast-insight](#)

Lactose Intolerance Market - <https://www.delveinsight.com/report-store/lactose-intolerance-market>

Medical Marijuana Market - <https://www.delveinsight.com/report-store/medical-marijuana-market-insight>

Asperger Syndrome Market - <https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market>

Catheter Stabilization Devices Market - <https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market>

## About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj

DelveInsight

+91 96502 13330

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/779239016>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.